Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma

被引:23
作者
Shinmura, Hiroki [1 ]
Yoneyama, Koichi [1 ]
Harigane, Eika [1 ]
Tsunoda, Yohei [1 ]
Fukami, Takehiko [1 ]
Matsushima, Takashi [1 ]
Takeshita, Toshiyuki [2 ]
机构
[1] Musashikosugi Hosp, Nippon Med Sch, Obstet & Gynecol, Kawasaki, Kanagawa 2118533, Japan
[2] Nippon Med Sch, Obstet & Gynecol, Bunkyo Ku, Tokyo, Japan
关键词
ovarian neoplasms; ovarian cysts; MUCINOUS BORDERLINE TUMORS; MALIGNANT-TRANSFORMATION; CLEAR-CELL; CANCER; ADENOCARCINOMA; PREMENOPAUSAL; EXPRESSION; BENIGN; CYST; LINK;
D O I
10.1136/ijgc-2020-001210
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. This study investigated the significance of preoperative tumor markers and clinical characteristics in distinguishing endometriosis-related ovarian neoplasms from ovarian endometrioma. Methods A case-control study was conducted on 283 women who were diagnosed with confirmed pathology with endometriosis-related ovarian neoplasms (n=21) and ovarian endometrioma (n=262) at a single institution from April 2008 to April 2018. The serum CA125, CA19-9, carcinoembryogenic antigen (CEA), sialyl Lewis-x antigen (SLX), and lactate dehydrogenase (LDH) levels, age, tumor size, and the presence of mural nodule of the patients were analyzed. Results Patients with endometriosis-related ovarian neoplasms were more likely to be older (48 (range, 26-81) vs 39 (range, 22-68) years, P<0.001), have higher levels of CA19-9 (42 vs 19 U/mL, P=0.013), CEA (1.3 vs 0.84 ng/mL, P=0.007), SLX (41 vs 33 U/mL, P=0.050), and LDH (189 vs 166 U/mL, P<0.001) and larger tumor size (79 vs 55 mm, P=0.001), and present with mural nodule (85.7 vs 4.5 %, P<0.001) than those with ovarian endometrioma. The CA125 levels did not significantly differ between the two groups. The area under the curve for each factor was as follows: CA19-9 level, 0.672 (95% CI 0.52 to 0.83; P=0.013); CEA level, 0.725 (95% CI 0.58 to 0.87; P=0.007); SLX level, 0.670 (95% CI 0.53 to 0.84; P=0.050); LDH level, 0.800 (95% CI 0.70 to 0.90; P<0.001); age, 0.775 (95% CI 0.65 to 0.90; P<0.001); and tumor size, 0.709 (95% CI 0.56 to 0.86; P=0.001). Age was a better marker than CA19-9, CEA, and SLX levels according to the receiver operating characteristic curve analysis. The optimal cut-off values for age and tumor size were 47 years and 80 mm, respectively. Conclusions The assessment of serum CA19-9, CEA, SLX, and LDH levels may be a useful tool in the preoperative evaluation to differentiate between endometriosis-related ovarian neoplasms and ovarian endometrioma.
引用
收藏
页码:831 / 836
页数:6
相关论文
共 31 条
[1]   Loss of ARID1A Expression Is an Early Molecular Event in Tumor Progression From Ovarian Endometriotic Cyst to Clear Cell and Endometrioid Carcinoma [J].
Ayhan, Ayse ;
Mao, Tsui-Lien ;
Seckin, Tamer ;
Wu, Chen-Hsuan ;
Guan, Bin ;
Ogawa, Hiroshi ;
Futagami, Masayuki ;
Mizukami, Hiroki ;
Yokoyama, Yoshihito ;
Kurman, Robert J. ;
Shih, Ie-Ming .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (08) :1310-1315
[2]   Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis [J].
Bandiera, Elisabetta ;
Zanotti, Laura ;
Fabricio, Aline S. C. ;
Bucca, Elisa ;
Squarcina, Elisa ;
Romani, Chiara ;
Tassi, Renata ;
Bignotti, Eliana ;
Todeschini, Paola ;
Tognon, Germana ;
Romagnolo, Cesare ;
Gion, Massimo ;
Sartori, Enrico ;
Maggino, Tiziano ;
Pecorelli, Sergio ;
Ravaggi, Antonella .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (09) :1815-1824
[3]   Endometriosis-Associated Ovarian Cancer Population Characteristics and Prognosis [J].
Barreta, Amilcar ;
Sarian, Luis ;
Ferracini, Amanda Canato ;
Eloy, Larissa ;
Carvalho Brito, Angelo Borsarelli ;
Andrade, Liliana de Angelo ;
Derchain, Sophie .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (07) :1251-1257
[4]   Molecular profiling and molecular classification of endometrioid ovarian carcinomas [J].
Cybulska, Paulina ;
Paula, Arnaud Da Cruz ;
Tseng, Jill ;
Leitao, Mario M., Jr. ;
Bashashati, Ali ;
Huntsman, David G. ;
Nazeran, Tayyebeh M. ;
Aghajanian, Carol ;
Abu-Rustum, Nadeem R. ;
DeLair, Deborah F. ;
Shah, Sohrab P. ;
Weigelt, Britta .
GYNECOLOGIC ONCOLOGY, 2019, 154 (03) :516-523
[5]  
Fadare Oluwole, 2019, Surg Pathol Clin, V12, P529, DOI 10.1016/j.path.2019.01.009
[6]  
Fukunaga M, 1998, MODERN PATHOL, V11, P784
[7]   Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses [J].
Gentry-Maharaj, Aleksandra ;
Burnell, Matthew ;
Dilley, James ;
Ryan, Andy ;
Karpinskyj, Chloe ;
Gunu, Richard ;
Mallett, Susan ;
Deeks, Jon ;
Campbell, Stuart ;
Jacobs, Ian ;
Sundar, Sudha ;
Menon, Usha .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 222 (01)
[8]   CLEAR CELL ADENOCARCINOMA OF THE OVARY - A CLINICAL ANALYSIS AND COMPARISON WITH SEROUS CARCINOMA [J].
JENISON, EL ;
MONTAG, AG ;
GRIFFITHS, CT ;
WELCH, WR ;
LAVIN, PT ;
GREER, J ;
KNAPP, RC .
GYNECOLOGIC ONCOLOGY, 1989, 32 (01) :65-71
[9]   Predictive factors for the presence of malignant transformation of pelvic endometriosis [J].
Kadan, Yfat ;
Fiascone, Stephen ;
McCourt, Carolyn ;
Raker, Chris ;
Granai, C. O. ;
Steinhoff, Margaret ;
Moore, Richard G. .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 185 :23-27
[10]   Endocervical-like (Mullerian) mucinous borderline tumours of the ovary are frequently associated with the KRAS mutation [J].
Kim, Kyu-Rae ;
Choi, Jene ;
Hwang, Jeong-Eun ;
Baik, Young-Ae ;
Shim, Jeong Yeon ;
Kim, Yong Man ;
Robboy, Stanley J. .
HISTOPATHOLOGY, 2010, 57 (04) :587-596